Name of this trial: BGB-11417-303/CLL-RR1
What type of cancer is this for? Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Who is this trial for? Relapsed and/or Refractory
What biomarkers are involved? CLL Cytogenics (eg, del(17p), del(11q), del(13q), and trisomy 12), complex karyotype, and the mutational status of relevant genes such as IGHV, TP53, and other CLL-related prognosis mutations.
What is the National Clinical Trial #? NCT06943872; https://www.clinicaltrials.gov/study/NCT06943872
Brief summary of this trial: A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Need to know: Have confirmed diagnosis of CLL/SLL and received one or more prior therapies for CLL/SLL. For reach line of therapy, patients must have received at least 2 cycles of therapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065